Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts. Show more

225 Franklin Street, Boston, MA, 02110, United States

https://ateapharma.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

358.6M

52 Wk Range

$2.46 - $4.80

Previous Close

$4.59

Open

$4.63

Volume

439,701

Day Range

$4.63 - $4.74

Enterprise Value

-154.7M

Cash

329.3M

Avg Qtr Burn

-40.38M

Insider Ownership

13.50%

Institutional Own.

78.16%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Bemnifosbuvir + Ruzasvir (RZR) Details Hepatitis C Virus Infection	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AT-587 (Nucleotide Analog) Details Hepatitis E Virus Infection	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AT-527 (Bemnifosbuvir) Details COVID-19, Infectious disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AT-752 Details Infectious disease, Dengue Fever	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AT-787 (fixed-dose combination of AT-527 & 777) Details Hepatitis C	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.